X‑ray Crystallography of a Nanobody/JAM‑1 Complex Informs Barrier Weakening and Enhanced Drug Permeability in a Cellular Blood–Brain Barrier Model
- 1The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia
- 2Department of Medical Biology, The University of Melbourne, Parkville, Melbourne, VIC 3010, Australia
- 3Research School of Biology, The Australian National University, Acton, Canberra, ACT 2600, Australia
Abstract
For pharmacological treatments of brain disorders, the blood–brain barrier (BBB) poses a formidable obstacle, tightly restricting the cerebral uptake of therapeutic agents. Tight junction (TJ) binders, including peptides, proteins, and monoclonal antibodies, that specifically bind to the extracellular domains (ECDs) of TJ proteins are increasingly being explored as BBB-weakening agents for enhanced drug delivery to the brain. Given that nanobodies (Nbs) can access epitopes that are often inaccessible to conventional antibodies, we obtained 16 Nbs with unique CDRs via immunization of alpaca with the ECD of either human (h) or murine JAM-1 (mJAM-1), a major TJ protein. Twelve Nb candidates exhibited high-affinity binding to mJAM-1, as measured by surface plasmon resonance (SPR), and these interactions were further validated for 9 Nbs by immunostaining of JAM-1-overexpressing cells. Five Nbs were found to weaken the barrier of the eGFP-hCldn5-MDCKII cellular monolayer, as shown by reduced transendothelial electrical resistance (TEER). X-ray crystallography revealed that the lead barrier-weakening Nb, E6, binds to the membrane-proximal nondimeric D2 domain of mJAM-1. Mutating key residues at this interface eliminated the BBB-weakening effect of E6, as evidenced by unaltered sodium fluorescence (NaFI) leakage in both eGFP-hCldn5-MDCKII and mJAM1-mGL-MDCKII cellular monolayers compared with the nontreated control. Our study highlights the potential of JAM-1-targeting Nbs as BBB modulators, offering a promising approach for generating TJ binders to enhance brain drug delivery.
Related
- A pilot cohort study of blood brain barrier permeability in Alzheimer’s disease using dynamic contrast enhanced magnetic resonance imaging
- Engineering a bivalent anti-CsGRP78 nanobody via CDR grafting: in silico design and cytotoxic validation
- Artificial Intelligence-Driven Nanobody Engineering for Pathogen Recognition: From Functional Epitope Prioritization to Multimodal Foundation Models
- A PD‐L1 Nanobody‐Engineered Synthetic RNA Virus Enhances Hepatocellular Carcinoma Immunotherapy by Interfering PCSK9 and Upregulating MHC‐I
- Targeting the non-enzymatic function of DPP4 via a nanobody inhibits cerebral cavernous malformation progression.
BibTeX
@article{chen2026xray,
title = {{X‑ray Crystallography of a Nanobody/JAM‑1 Complex Informs Barrier Weakening and Enhanced Drug Permeability in a Cellular Blood–Brain Barrier Model}},
author = {Liyu Chen and Michael D. Healy and Haoyue Xi and Esteban Cruz and Mingze Xu and Rainbow Wing Bo Chan and Tishila Palliyaguru and Jonathan L. F. Lee and Wai-Hong Tham and Brett M. Collins and Jürgen Götz},
journal = {ACS Nano},
year = {2026},
month = oct,
doi = {10.1021/acsnano.6c07541},
url = {https://doi.org/10.1021/acsnano.6c07541},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - X‑ray Crystallography of a Nanobody/JAM‑1 Complex Informs Barrier Weakening and Enhanced Drug Permeability in a Cellular Blood–Brain Barrier Model
AU - Liyu Chen
AU - Michael D. Healy
AU - Haoyue Xi
AU - Esteban Cruz
AU - Mingze Xu
AU - Rainbow Wing Bo Chan
AU - Tishila Palliyaguru
AU - Jonathan L. F. Lee
AU - Wai-Hong Tham
AU - Brett M. Collins
AU - Jürgen Götz
PY - 2026
DA - 2026/10/30
JO - ACS Nano
DO - 10.1021/acsnano.6c07541
UR - https://doi.org/10.1021/acsnano.6c07541
AB - For pharmacological treatments of brain disorders, the blood–brain barrier (BBB) poses a formidable obstacle, tightly restricting the cerebral uptake of therapeutic agents. Tight junction (TJ) binders, including peptides, proteins, and monoclonal antibodies, that specifically bind to the extracellular domains (ECDs) of TJ proteins are increasingly being explored as BBB-weakening agents for enhanced drug delivery to the brain. Given that nanobodies (Nbs) can access epitopes that are often inaccessible to conventional antibodies, we obtained 16 Nbs with unique CDRs via immunization of alpaca with the ECD of either human (h) or murine JAM-1 (mJAM-1), a major TJ protein. Twelve Nb candidates exhibited high-affinity binding to mJAM-1, as measured by surface plasmon resonance (SPR), and these interactions were further validated for 9 Nbs by immunostaining of JAM-1-overexpressing cells. Five Nbs were found to weaken the barrier of the eGFP-hCldn5-MDCKII cellular monolayer, as shown by reduced transendothelial electrical resistance (TEER). X-ray crystallography revealed that the lead barrier-weakening Nb, E6, binds to the membrane-proximal nondimeric D2 domain of mJAM-1. Mutating key residues at this interface eliminated the BBB-weakening effect of E6, as evidenced by unaltered sodium fluorescence (NaFI) leakage in both eGFP-hCldn5-MDCKII and mJAM1-mGL-MDCKII cellular monolayers compared with the nontreated control. Our study highlights the potential of JAM-1-targeting Nbs as BBB modulators, offering a promising approach for generating TJ binders to enhance brain drug delivery.
SN - 1936-0851
SN - 1936-086X
ER -